Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Blood (2019) 134 (23): 2036–2045.

https://doi.org/10.1182/blood.2019000069

Published: 2019

Includes: Supplemental data

Journal Articles

Relation of Pancreatic Iron Overload Detected By MRI with Disorders of Glucose Metabolism and Results of Liver, Cardiac and Pitutiary MRI Among Transfusion Dependent Thalassemia (TDT) Patients in Turkey

Zeynep Karakas, Cihangir Sevimli, Nurdan Gul, Rana Comert, Memduh Dursun

Blood (2018) 132 (Supplement 1): 2350.

https://doi.org/10.1182/blood-2018-99-115356

Published: 2018

Journal Articles

Central Nervous System Fungal Infections in Children with Leukemia, Risk Factors and Outcome: A Multicentric Study

Rejin Kebudi, MD, Serap Karaman, MD, Hande Kizilocak, Zeynep Karakas, Melike Sezgin Evim, Bengü Demirag, Zuhre Kaya, Husniye Nese Yarali, Umran Caliskan, B.Sahin Karagun, Canan Albayrak, MD, Sebnem Yilmaz, Deniz Karapinar, Ekrem Unal, MD, Adalet Meral Gunes, Neryal Tahta, Zeliha Guzelkucuk, Ulker Kocak, MD, Tiraje Celkan, MD

Blood (2018) 132 (Supplement 1): 5169.

https://doi.org/10.1182/blood-2018-99-112712

Published: 2018

Journal Articles

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

Ali T. Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyère Mahuzier, Brian Gadbaw, Yesim Aydinok

Blood (2018) 131 (2): 263–265.

https://doi.org/10.1182/blood-2017-06-790121

Published: 2018

Includes: Supplemental data

Journal Articles

IKZF1 Deletions at Diagnose and Relapse of Childhood B-ALL

Yücel Erbilgin, Sinem Firtina, PhD, Ozden Hatirnaz Ng, PhD, Tiraje Celkan, MD, Zeynep Karakas, MD, Seniye Sema Anak, MD, Nazan Sarper, MD, Emine Zengin, MD, Ahmet Eskazan, MD, Muge Sayitoglu, PhD, Ugur Ozbek, MD, PhD

Blood (2017) 130 (Supplement 1): 5110.

https://doi.org/10.1182/blood.V130.Suppl_1.5110.5110

Published: 2017

Journal Articles

Turkish National Severe Congenital Neutropenia Registry

Blood (2016) 128 (22): 4916.

https://doi.org/10.1182/blood.V128.22.4916.4916

Published: 2016

Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD

Blood (2016) 128 (22): 852.

https://doi.org/10.1182/blood.V128.22.852.852

Published: 2016

Journal Articles

Different Response Patterns to Inactivated, Subunit or Live Attenuated Vaccines in Children after Treatment for Malignancies and Bone Marrow Transplantation

Sema S Anak, Elif Erdem Ozcan, Ayse Kilic, Mustafa Onel, Ayhan Ozguven, Aysegul Unuvar, Zeynep Karakas, Gulyuz Ozturk, Ali Agacfidan, Omer Devecioglu, Leyla Agaoglu, Yurdanur Kilinc

Blood (2015) 126 (23): 5478.

https://doi.org/10.1182/blood.V126.23.5478.5478

Published: 2015

Journal Articles

Total Oxidant and Antioxidant Capacity in Patients with Transfusion Dependent and Nondependent Beta Thalassemia

Zeynep Karakas, Yasin Yilmaz, Dolay Damla Celik, Agageldi Annayev, Selcan Demirel, Serap Erdem Kuruca

Blood (2015) 126 (23): 4573.

https://doi.org/10.1182/blood.V126.23.4573.4573

Published: 2015

Journal Articles

Efficacy and Safety of Deferasirox Across Underlying Non-Transfusion-Dependent Thalassemia Syndromes: 1-Year Results from the Thetis Study

M Domenica Cappellini, Vip Viprakasit, Yesim Aydinok, John B Porter, Yong-Rong Lai, Noppadol Siritanaratkul, Zeynep Karakas, Antonis Kattamis, Candace Wang, Zewen Zhu, Felicity Schaefer, Ali T Taher

Blood (2015) 126 (23): 3366.

https://doi.org/10.1182/blood.V126.23.3366.3366

Published: 2015

Journal Articles

Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study

Ali T Taher, M Domenica Cappellini, Yesim Aydinok, John B. Porter, Zeynep Karakas, Vip Viprakasit, Noppadol Siritanaratkul, Antonis Kattamis, Candace Wang, Zewen Zhu, Victor Joaquin, Marie José Uwamahoro, Yong-Rong Lai

Blood (2015) 126 (23): 2153.

https://doi.org/10.1182/blood.V126.23.2153.2153

Published: 2015

Journal Articles

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Yesim Aydinok, Antonis Kattamis, M. Domenica Cappellini, Amal El-Beshlawy, Raffaella Origa, Mohsen Elalfy, Yurdanur Kilinç, Silverio Perrotta, Zeynep Karakas, Vip Viprakasit, Dany Habr, Niculae Constantinovici, Junwu Shen, John B. Porter

Blood (2015) 125 (25): 3868–3877.

https://doi.org/10.1182/blood-2014-07-586677

Published: 2015

Includes: Supplemental data

Journal Articles

Evaluation of Early Glomerulopathy and Tubulopathy in Patients with Transfusion Dependent Thalassemia

Zeynep Karakas, Prof, Agageldi Annayev, MD, Altan Yalciner, MD, Sevinc Emre, Prof

Blood (2014) 124 (21): 4904.

https://doi.org/10.1182/blood.V124.21.4904.4904

Published: 2014

Journal Articles

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Yesim Aydinok, MD, Antonis Kattamis, MD, M Domenica Cappellini, MD, Amal El-Beshlawy, MD, Raffaella Origa, MD, Mohsen Elalfy, MD, Yurdanur Kilinç, MD, Silverio Perrotta, MD, Zeynep Karakas, MD, Vip Viprakasit, MD, Dany Habr, MD, Antje Wegener, MD, Junwu Shen, PhD, John B Porter, MD

Blood (2013) 122 (21): 2257.

https://doi.org/10.1182/blood.V122.21.2257.2257

Published: 2013

Journal Articles

Genetic and Epigenetic Profile Of Early Relapsed Childhood ALL

Yucel Erbilgin, Ozden Hatirnaz Ng, PhD, Sinem Firtina, Tiraje Celkan, Sema Anak, MD, Zeynep Karakas, MD, Aykan Ozguven, MD, Nazan Sarper, MD, Emine Zengin, MD, Emine Turkkan, MD, Didem Yalcin Atay, MD, Yuk Yin Ng, PhD, Omer Dogru, MD, Muge Sayitoglu, PhD, Ugur Ozbek

Blood (2013) 122 (21): 1380.

https://doi.org/10.1182/blood.V122.21.1380.1380

Published: 2013

Journal Articles

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Ali T Taher, MD, John B Porter, MD, Vip Viprakasit, MD, DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppadol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Jacqueline Ros, PhD, Zewen Zhu, M Domenica Cappellini, MD

Blood (2012) 120 (21): 3258.

https://doi.org/10.1182/blood.V120.21.3258.3258

Published: 2012

Journal Articles

Reachthem: Baseline Characteristics of a 3 Year Prospective Registry of Children with Hemoglobinopathies Receiving Oral Iron Chelators in the Treatment of Transfusional Iron Overload

Bülent Antmen, M.D., Prof., Zeynep Karakas, M.D., Prof., Gonul Oktay, M.D., Mehmet Akin, M.D., Gonul Aydogan, M.D., Zafer Salcioglu, M.D., Canan Vergin, M.D., Assoc. Prof., Selma Unal, M.D., Assoc. Prof., Kerem Organ, M.D., Aycin Canatar, Ertan Koseoglu, Mehmet Akif Yesilipek, M.D., Prof

Blood (2012) 120 (21): 5169.

https://doi.org/10.1182/blood.V120.21.5169.5169

Published: 2012

Journal Articles

Frequency of Agranulocytosis and Mild Neutropenia During Deferiprone Therapy in Clinical Practice

Mohsen Saleh Elalfy, MD, Shebl Said Shebl, MD, Mohamed A. Badr, MD, Prof, Usama R. Elsafy, MD, Prof, Mostafa A. Salama, MD, Prof, Youssef Al-Tonbary, MD, Yousryeia Abdel Rahman, MD, Mohamad H. Qari, MD, Ghazi Abdullah Al Damnhouri, MD, Zakaria Al Hawsawi, MD, Yasser Ahmed Wali, MD, Prof, M. Akif Yesilipek, MD, Prof, Yurdanur Kilinc, MD, Dilek Yazman, MD, Zeynep Karakas, MD, Fernando Tricta, MD

Blood (2012) 120 (21): 996.

https://doi.org/10.1182/blood.V120.21.996.996

Published: 2012

Journal Articles

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Ali T. Taher, John Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Jacqueline Ros, Yiyun Zhang, Dany Habr, Maria Domenica Cappellini

Blood (2012) 120 (5): 970–977.

https://doi.org/10.1182/blood-2012-02-412692

Published: 2012

Includes: Supplemental data

Journal Articles

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

Ali T Taher, MD, John B. Porter, MD, Vip Viprakasit, MD; DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppodol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Jacqueline Ros, PhD, Yiyun Zhang, Dany Habr, MD, M. Domenica Cappellini, MD

Blood (2011) 118 (21): 902.

https://doi.org/10.1182/blood.V118.21.902.902

Published: 2011

NARROW

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Relation of Pancreatic Iron Overload Detected By MRI with Disorders of Glucose Metabolism and Results of Liver, Cardiac and Pitutiary MRI Among Transfusion Dependent Thalassemia (TDT) Patients in Turkey

Central Nervous System Fungal Infections in Children with Leukemia, Risk Factors and Outcome: A Multicentric Study

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

IKZF1 Deletions at Diagnose and Relapse of Childhood B-ALL

Turkish National Severe Congenital Neutropenia Registry

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Different Response Patterns to Inactivated, Subunit or Live Attenuated Vaccines in Children after Treatment for Malignancies and Bone Marrow Transplantation

Total Oxidant and Antioxidant Capacity in Patients with Transfusion Dependent and Nondependent Beta Thalassemia

Efficacy and Safety of Deferasirox Across Underlying Non-Transfusion-Dependent Thalassemia Syndromes: 1-Year Results from the Thetis Study

Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Evaluation of Early Glomerulopathy and Tubulopathy in Patients with Transfusion Dependent Thalassemia

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Genetic and Epigenetic Profile Of Early Relapsed Childhood ALL

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Reachthem: Baseline Characteristics of a 3 Year Prospective Registry of Children with Hemoglobinopathies Receiving Oral Iron Chelators in the Treatment of Transfusional Iron Overload

Frequency of Agranulocytosis and Mild Neutropenia During Deferiprone Therapy in Clinical Practice

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only